PL2141996T3 - Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu - Google Patents

Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu

Info

Publication number
PL2141996T3
PL2141996T3 PL08826313T PL08826313T PL2141996T3 PL 2141996 T3 PL2141996 T3 PL 2141996T3 PL 08826313 T PL08826313 T PL 08826313T PL 08826313 T PL08826313 T PL 08826313T PL 2141996 T3 PL2141996 T3 PL 2141996T3
Authority
PL
Poland
Prior art keywords
preventing
methods
infectious diseases
treating infectious
gallium compounds
Prior art date
Application number
PL08826313T
Other languages
English (en)
Inventor
Daniel P Perl
Sharon Moalem
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Publication of PL2141996T3 publication Critical patent/PL2141996T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL08826313T 2007-04-02 2008-03-28 Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu PL2141996T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90965807P 2007-04-02 2007-04-02
PCT/US2008/058666 WO2009009171A2 (en) 2007-04-02 2008-03-28 Methods for preventing or treating infectious diseases using gallium compounds
EP08826313A EP2141996B1 (en) 2007-04-02 2008-03-28 Methods for preventing or treating infectious diseases using gallium compounds

Publications (1)

Publication Number Publication Date
PL2141996T3 true PL2141996T3 (pl) 2013-05-31

Family

ID=39794789

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08826313T PL2141996T3 (pl) 2007-04-02 2008-03-28 Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu

Country Status (10)

Country Link
US (6) US8895077B2 (pl)
EP (2) EP2526773A1 (pl)
JP (4) JP5559031B2 (pl)
KR (1) KR101217415B1 (pl)
CN (1) CN101677574B (pl)
CA (1) CA2682745C (pl)
ES (1) ES2401045T3 (pl)
PL (1) PL2141996T3 (pl)
PT (1) PT2141996E (pl)
WO (1) WO2009009171A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060004185A1 (en) * 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
EP1962774B1 (en) * 2005-11-01 2014-01-01 Mount Sinai School of Medicine Growth control of oral and superficial microorganisms using gallium compounds
PL2141996T3 (pl) * 2007-04-02 2013-05-31 Sinai School Medicine Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu
US20090275655A1 (en) * 2008-04-30 2009-11-05 Genta Incorporated Pharmaceutical Gallium Compositions and Methods
US20090275654A1 (en) * 2008-04-30 2009-11-05 Genta Incorporated Pharmaceutical Gallium Compositions and Methods
AR074874A1 (es) 2008-12-23 2011-02-16 Biosource Pharm Inc Composiciones antibioticas para el tratamiento de infecciones gram negativas. metodo. uso. compuesto.
US9539233B2 (en) * 2009-05-04 2017-01-10 Aridis Pharmaceuticals Inc. Gallium formulation for the treatment and prevention of infectious diseases
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2013025545A2 (en) * 2011-08-15 2013-02-21 Buchanan Benjamin R Drug delivery systems and method of reducing foal infection by treating mares with gallium salts
AU2011383327B2 (en) 2011-12-15 2015-05-14 Colgate-Palmolive Company Oral care compositions
KR102065037B1 (ko) * 2015-09-30 2020-01-10 (주)아모레퍼시픽 진세노사이드 지방산 에스터 화합물, 이의 제조방법 및 이를 포함하는 화장료 조성물
JP7009396B2 (ja) * 2017-01-30 2022-01-25 ニュートリー株式会社 Ｍｒｓａ感染防御剤
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
JP7458622B2 (ja) * 2019-09-18 2024-04-01 学校法人東京農業大学 抗生物質耐性微生物の耐性を低下させる物質及び抗生物質耐性微生物の耐性を低下させる方法
CN111876879A (zh) * 2020-07-31 2020-11-03 储旭 抗菌面料及其制备方法
US20250281464A1 (en) * 2022-04-29 2025-09-11 Virginia Tech Intellectual Properties, Inc. Treatment of pathogenic neisseria sp. infection with triazole antifungal agents

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2071867A1 (en) * 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
US5574027A (en) * 1989-11-22 1996-11-12 Bernstein; Lawrence R. Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5258376A (en) * 1989-11-22 1993-11-02 Bernstein Lawrence R Pharmaceutical compositions of gallium complexes of 3-hydroxy-4-pyrones
US5686116A (en) 1990-01-12 1997-11-11 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Methods of enhancing repair, healing and augmentation of bone implants
US5556645A (en) 1990-01-12 1996-09-17 Bockman; Richard Methods of enhancing wound healing and tissue repair
GB9009437D0 (en) * 1990-04-26 1990-06-20 Glaxo Group Ltd Chemical compounds
US5286480A (en) * 1992-06-29 1994-02-15 The Procter & Gamble Company Use of N-acetylated amino acid complexes in oral care compositions
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
AU4399296A (en) * 1994-12-19 1996-07-10 Lauteral Limited A combination product comprising nitazoxanide and an anti-ulcer agent
AUPN881396A0 (en) * 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
US5843936A (en) * 1996-06-28 1998-12-01 Bernstein; Lawrence R. Topical administration of azaspiranes to prevent or treat skin conditions associated with hyperproliferation of keratinocytes
US5747482A (en) * 1996-07-30 1998-05-05 Bernstein; Lawrence R. Methods and compositions to inhibit keratinocyte proliferation
US6203822B1 (en) 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
AU6028598A (en) 1997-01-09 1998-08-03 Emory University Non-iron metalloporphyrins and methods of use
US6397242B1 (en) * 1998-05-15 2002-05-28 Vmware, Inc. Virtualization system including a virtual machine monitor for a computer with a segmented architecture
US6297242B1 (en) 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
AU775459B2 (en) * 1999-10-04 2004-08-05 Lawrence R. Bernstein Gallium complexes of 3-hydroxy-4-pyrones to treat infection by intracellular prokaryotes, DNA viruses and retroviruses
US20020068761A1 (en) 1999-10-04 2002-06-06 Bernstein Lawrence R. Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
JP4484468B2 (ja) * 2002-08-20 2010-06-16 株式会社メニコン コンタクトレンズの消毒方法及びそのための消毒液
WO2005055723A1 (en) * 2003-12-04 2005-06-23 The University Of Iowa Research Foundation Gallium inhibits biofilm formation
ZA200605583B (en) * 2003-12-17 2009-06-24 Titan Pharmaceuticals Inc Use of gallium to treat inflammatory arthritis
EP1962774B1 (en) * 2005-11-01 2014-01-01 Mount Sinai School of Medicine Growth control of oral and superficial microorganisms using gallium compounds
AU2007208169A1 (en) * 2006-01-30 2007-08-02 Lawrence R. Bernstein Use of gallium to treat biofilm-associated infectons
WO2008036787A1 (en) 2006-09-22 2008-03-27 C.R. Bard, Inc. Antimicrobial compositions containing gallium
PL2141996T3 (pl) * 2007-04-02 2013-05-31 Sinai School Medicine Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu

Also Published As

Publication number Publication date
US20180028564A1 (en) 2018-02-01
KR20100016051A (ko) 2010-02-12
CN101677574B (zh) 2014-05-07
US20190175644A1 (en) 2019-06-13
KR101217415B1 (ko) 2013-01-02
EP2526773A1 (en) 2012-11-28
US8895077B2 (en) 2014-11-25
EP2141996A4 (en) 2010-04-14
ES2401045T3 (es) 2013-04-16
CA2682745A1 (en) 2009-01-15
WO2009009171A2 (en) 2009-01-15
EP2141996A2 (en) 2010-01-13
JP6890843B2 (ja) 2021-06-18
JP2014193914A (ja) 2014-10-09
WO2009009171A3 (en) 2009-03-19
CN101677574A (zh) 2010-03-24
CA2682745C (en) 2014-12-23
US20150064284A1 (en) 2015-03-05
US20160375056A1 (en) 2016-12-29
US20080241275A1 (en) 2008-10-02
US20150352148A1 (en) 2015-12-10
JP2019135269A (ja) 2019-08-15
PT2141996E (pt) 2013-03-07
JP2017114887A (ja) 2017-06-29
EP2141996B1 (en) 2012-11-21
JP5559031B2 (ja) 2014-07-23
JP2010523577A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
PL2141996T3 (pl) Sposoby zapobiegania lub leczenia chorób infekcyjnych z zastosowaniem związków galu
IL257418A (en) Methods for treating addiction
IL211509A0 (en) Compounds for the treatment of hepatitis c
IL209895A0 (en) Compounds for treating beta-amyloidoses
GB2454555B (en) Alkoxy compounds for disease treatment
ZA200906129B (en) Compounds for the treatment of hepatitis c
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
AP2012006064A0 (en) Compounds and methods for treating influenza.
ZA201109031B (en) Compounds useful for treating aids
GB0816679D0 (en) Compounds for treating viral infections
ZA201007216B (en) Agent for treating disease
IL207892A0 (en) Agent for treating disease
IL207891A0 (en) Agent for treating disease
EP2170311A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
ZA201000923B (en) Compounds for the treatment of hepatitis c
EP2081437A4 (en) METHODS OF TREATING OR PREVENTING INFESTATION
ZA201204845B (en) Agents for treating disease
PT2341937E (pt) Composição para tratamento de doença
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
GB201008346D0 (en) Methods and compounds for phototransfer
ZA200903242B (en) Treatment for multiple myeloma
ZA201000867B (en) Methods for treating dependence